Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-02-26 pm EST 5-day change 1st Jan Change
118.7 USD -0.64% Intraday chart for Abbott Laboratories +4.10% +7.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AbbVie CEO to Retire; COO Robert Michael Named Successor MT
AbbVie Names Robert Michael to Succeed Richard Gonzalez as CEO DJ
Abbott Laboratories Maintains Quarterly Dividend at $0.55 a Share, Payable May 15 to Holders of Record April 15. MT
Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024 CI
Abbott Laboratories Says FDA Advisory Committee Backs TriClip System for Treatment of Tricuspid Regurgitation MT
Correction to Abbott Laboratories Article DJ
Abbott Laboratories Says FDA Independent Panel Votes to Approve Heart Device DJ
FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve CI
Abbott's heart valve repair device gets US FDA advisers' backing RE
US FDA staff raises no new concerns about Abbott's heart device RE
Dexcom beats profit estimates on strong demand for glucose monitors RE
Zimmer Biomet forecasts upbeat 2024 profit on steady medical devices demand RE
Insulet's Omnipod 5 Receives CE Mark for Abbott FreeStyle Libre 2 Plus Integration MT
Edwards Lifesciences beats quarterly estimates on strong heart device sales RE
Abbott Labs must face lawsuit over PediaSure height claims RE
Drugmaker Abbott India's Q3 profit rises on strong demand RE
Abbott launches protein shake brand to help people on weight-loss drug RE
Abbott Laboratories Launches Protality Protein Drink MT
Abbott Laboratories Announces the Launch of Its New PROTALITY Brand CI
Abbott Laboratories Enters into Five Year Credit Agreement and Terminates All Commitments Outstanding Under the Five Year Credit Agreement CI
Chinese medical device firm Mindray plans $927 million deal to control APT Medical RE
Barclays Raises Abbott Laboratories' Price Target to $141 From $133, Keeps Overweight Rating MT
Abbott Laboratories' Underlying 'Solid' Growth Profile Remains Intact, RBC Capital Markets Says MT
Abbott Laboratories Obtains FDA Approval to Launch Deep Brain Stimulation System for Movement Disorders MT
Raymond James Adjusts Price Target on Abbott Laboratories to $127 From $124, Maintains Outperform Rating MT
Chart Abbott Laboratories
More charts
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (38%); - vascular devices (21%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (17.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (11.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (12.7%). Net sales are distributed geographically as follows: the United States (41.5%), Germany (5.4%), China (4.9%), Japan (4.4%), India (3.8%), Switzerland (3.1%), Canada (2.9%) and other (34%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
118.7 USD
Average target price
124.5 USD
Spread / Average Target
+4.93%
Consensus
  1. Stock
  2. Equities
  3. Stock Abbott Laboratories - Nyse
  4. News Abbott Laboratories
  5. NeuroOne Medical Technologies Names Christopher Volker as Chief Operating Officer
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW